| 분자 | Cat. No. | Product Name | 종 | Host | 구조 | 순도 | Activity | 규격 및 가격 |
|---|---|---|---|---|---|---|---|---|
| SLAMF7 | HOT SL7-HP2H6 | PE-Labeled Human SLAMF7 / CRACC / CD319 Protein, His TagStar Staining | Human | HEK293 | $360.00 25tests | |||
| SLAMF7 | HOT SL7-H5225 | Human SLAMF7 / CRACC / CD319 Protein, His Tag, low Endotoxin (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $270.00 100ug | |
| SLAMF7 | HOT SL7-R52H7 | Rhesus macaque SLAMF7 / CRACC / CD319 Protein, His Tag (MALS verified) | Rhesus macaque | HEK293 | ![]() | MALSSDS-PAGE | $360.00 100ug | |
| SLAMF7 | HOTAvitag SL7-H82E0 | Biotinylated Human SLAMF7 / CRACC / CD319 Protein, Avitag™,His Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $360.00 25ug | |
| SLAMF7 | HOT SL7-HP2H3 | PE-Labeled Human SLAMF7 / CRACC / CD319 Protein, His Tag (Site-specific conjugation) | Human | HEK293 | ![]() | $360.00 25tests | ||
| SLAMF7 | Human SLAMF7 / CRACC / CD319 Protein, Fc Tag | Human | HEK293 | ![]() | SDS-PAGE | $260.00 100ug | ||
| SLAMF7 | FITC-Labeled Human SLAMF7 / CRACC / CD319 Protein, His Tag | Human | HEK293 | ![]() | SDS-PAGE | $330.00 25ug | ||
| SLAMF7 | Mouse SLAMF7 / CRACC / CD319 Protein, Mouse IgG2a Fc Tag, low endotoxin | Mouse | HEK293 | ![]() | SDS-PAGE | $310.00 100ug |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| SLAMF7 CAR-T cell therapy (Wuerzburg University Hospital) | Phase 2 Clinical | University Hospital Würzburg | Multiple Myeloma | 상세 | |
| dual anti-CS-1/anti-BCMA CAR T-cell therapy (Wuhan Sian Medical Technology) | Phase 1 Clinical | Wuhan Sian Biotechnology Co Ltd | Multiple Myeloma | 상세 | |
| BCMA-CS1 cCAR T-cell therapy | Phase 1 Clinical | iCell Gene Therapeutics LLC | Multiple Myeloma | 상세 | |
| SA102-CAR-T | SA-102; SA102 | Phase 1 Clinical | Wuhan Sian Biotechnology Co Ltd | Multiple Myeloma | 상세 |
| WS-CART-CS1 | WS-CART-CS1 | Phase 1 Clinical | Paula C. & Rodger O. Riney Blood Cancer Research, Washington University School Of Medicine | Multiple Myeloma | 상세 |
| MB-104 | MB-104; MB-105; MB-104 CS1 CAR; MB-105 PSCA CAR | Phase 1 Clinical | City Of Hope National Medical Center | Glioblastoma; Multiple Myeloma; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms | 상세 |
| CS1 Targeted CAR T-cells (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | 상세 | |
| CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology) | Clinical | Wuhan BioRaid Biotechnology Co Ltd | Hematologic Neoplasms | 상세 |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 가장 빠른 브랜드 이름 | 가장 빠른 승인 국가 | 가장 빠른 적응증 | 가장 빠른 승인 회사 | 가장 빠른 승인 날짜 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|---|---|---|---|---|
| Elotuzumab | PDL-063; HuLuc-63; BMS-901608 | Approved | Abbvie Inc, Bristol-Myers Squibb Company | Empliciti | United States | Multiple Myeloma | Bristol-Myers Squibb Company | 2015-11-30 | Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Leukemia, Plasma Cell; Lymphoma; Multiple Myeloma; Polycythemia Vera; Primary Myelofibrosis; Smoldering Multiple Myeloma; Thrombocythemia, Essential | 상세 |